5 citations
,
April 2016 in “PubMed” Cetuximab often causes skin problems, but they can be managed without stopping treatment.
70 citations
,
December 2008 in “Cancer Research” CXCR2 in skin cells promotes tumor growth.
42 citations
,
September 2012 in “PLoS ONE” Bezafibrate treatment improved skin and spleen health in aging mice but didn't extend lifespan.
February 2021 in “Reactions Weekly” Finasteride and dutasteride may cause macular abnormalities.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
January 2008 in “中山醫學大學醫學研究所學位論文” Danthron from Rhubarb causes melanoma cells to stop growing and die.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
13 citations
,
August 2018 in “Life sciences” Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.
July 2024 in “Journal of Investigative Dermatology” JW0061 may be a new treatment for hair loss by promoting hair growth through WNT signaling.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.
35 citations
,
May 2008 in “Journal of Clinical Oncology” A cancer patient died from a severe skin reaction after taking the drug cetuximab.
49 citations
,
December 2022 in “Pharmacological Reviews” Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
Early diagnosis and treatment of frontal fibrosing alopecia are crucial to prevent permanent hair loss.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.
2 citations
,
January 2025 in “Journal of Oncology Pharmacy Practice” Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
51 citations
,
March 2014 in “Nature Communications” Skin tumor regression is helped by retinoic acid signaling blocking Wnt signaling.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.